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on the Amplatzer Cardiac Plug After
Left Atrial Appendage OcclusionBjoern Plicht, MD,* Thomas F. M. Konorza, MD,* Philipp Kahlert, MD,*
Fadi Al-Rashid, MD,* Hagen Kaelsch, MD,* Rolf Alexander Jánosi, MD,*
Thomas Buck, MD,* Hagen S. Bachmann, MD,y Winfried Siffert, MD,y
Gerd Heusch, MD,z Raimund Erbel, MD*
Essen, GermanyObjectives This study sought to identify risk factors for thrombus formation on the Amplatzer Cardiac
Plug (ACP) (St. Jude Medical, St. Paul, Minnesota) after left atrial appendage occlusion.
Background Left atrial appendage occlusion with the ACP aims to reduce the risk of embolic stroke
and bleeding complications associated with vitamin K antagonists in patients with atrial ﬁbrillation.
Methods We performed transesophageal echocardiography before discharge and after 3, 6, and
12 months in 34 patients with atrial ﬁbrillation undergoing ACP implantation and receiving dual
antiplatelet therapy. Clinical, echocardiographic, and hemostaseological parameters were
retrospectively analyzed to identify risk factors for thrombus formation.
Results Three patients had thrombi before discharge, 3 more at the 3-month follow-up.
No differences were found in left atrial volume, left atrial appendage velocity, spontaneous echo
contrast, transmitral gradient, or mitral regurgitation between patients without or with thrombi.
CHADS2 (Congestion, Hypertension, Age, Diabetes, and Stroke) score (2.0  1.1 vs. 4.3  1.0),
CHA2DS2-VASc (CHADS2 plus Vascular Disease and Sex Category) score (5.2  1.3 vs. 6.8  0.8), and
pre-interventional platelet count (215.9  63.9/nl vs. 282.5  84.4/nl) were higher and ejection fraction
(50.6  11.4% vs. 39.7  10.6%) lower in those with thrombi. Factor 2, factor 5, or
methylenetetrahydrofolate reductase mutations and genetic variants associated with reduced
clopidogrel activity were not more frequent in patients with thrombi.
Conclusions Transesophageal echocardiography identiﬁed 17.6% of patients with thrombus
formation on the ACP despite dual antiplatelet therapy. CHADS2 and CHA2DS2-VASc scores, platelet
count, and ejection fraction are risk factors for such thrombus formation. (J Am Coll Cardiol Intv
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Abbreviations
and Acronyms
ACP = Amplatzer Cardiac
Plug
AF = atrial ﬁbrillation
CHADS2 = Congestion,
Hypertension, Age, Diabetes,
and Stroke
CHA2DS2-VASc = CHADS2
Plus Vascular Disease and
Sex Category
CYP = cytochrome P450
EF = ejection fraction
HAS-BLED = Hypertension,
Abnormal Liver or Renal
Function, Stroke, Bleeding,
Labile International
Normalized Ratio, Elderly,
Drug, or Alcohol Intake
LAA = left atrial appendage
TEE = transesophageal
echocardiography
VKA = vitamin K antagonists
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607Embolic stroke is the most serious complication in patients
with atrial ﬁbrillation (AF), and its annual risk ranges
between 1.9 and 18.2% (1). Oral anticoagulation with
vitamin K antagonists (VKA) is recommended in patients
with CHADS2 (Congestion, Hypertension, Age, Diabetes,
and Stroke) score 2 and reduces stroke risk (2). However,
the therapeutic range of VKA is narrow, and severe bleeding
is a serious side effect (3).
Up to 90% of emboli from nonvalvular AF originate in
the left atrial appendage (LAA) (4). Therefore, interven-
tional LAA occlusion was introduced to avoid long-term
oral anticoagulation, and the Amplatzer Cardiac Plug
(ACP) (St. Jude Medical, St. Paul, Minnesota) is such a
device. After ACP implantation, antiplatelet/antithrombotic
medication is mandatory until its endothelial coverage
is complete; the manufacturer’s instructions include dual
antiplatelet therapy for at least 1 month with discontinuation
of oral anticoagulation.
In our initial series of 34 patients undergoing ACP implan-
tation, we surprisingly detected 6 patients with thrombus
formation on the device in close follow-up by transesophageal
echocardiography (TEE). We then tried to retrospectively
identify clinical, echocardiographic, and hemostaseological
risk factors for thrombus formation.
Methods
Procedure. Between November 2009 and February 2011, 34
consecutivepatientswithAF,CHADS2 score2, and increased
bleeding risk under oral anticoagulation as reﬂected by HAS-
BLED (Hypertension, Abnormal Liver or Renal Function,
Stroke, Bleeding, Labile International Normalized Ratio,
Elderly, Drug, or Alcohol Intake) score 3 (1) underwent
ACP implantation at our institution after informed consent.
Under mild sedation, ﬂuoroscopy, and real-time
3-dimensional TEE, the device was delivered over a 10-F or
13-F sheath into the left atrium after transseptal puncture
(Baylis NRG transseptal needle, Baylis Medical, Montreal,
Canada). The device was ﬁrst anchored in the LAA landing
zone, approximately 1 cm behind the oriﬁce; the disk was
then unfolded to cover the LAA entrance (Fig. 1), optimally
covering the rim between LAA and the upper left pulmo-
nary vein (Fig. 2). A wiggle maneuver conﬁrmed the safe
placement before its ﬁnal release. Patients received up to
12,500 U of unfractionated heparin intravenously to achieve
an activated clotting time >250 s. Oral anticoagulation with
VKA was discontinued prior to the procedure to achieve an
international normalized ratio <1.4. Dual antiplatelet
therapy with 100 mg of aspirin daily and 75 mg of clopi-
dogrel daily after a 600-mg loading dose given in the
catheterization laboratory post-procedurally was adminis-
tered for at least 6 months according to our clinic’s standard
protocol. Eight patients were pre-treated with clopidogrel
before so they received a 300-mg loading dose.Data collection. From the patients’ ﬁles, baseline platelet
count and plasma ﬁbrinogen; diabetes mellitus; type of AF;
and CHADS2, CHA2DS2-VASc (CHADS2 Plus Vascular
Disease and Sex Category), and HAS-BLED scores were
retrospectively identiﬁed.
Transthoracic echocardiography and real-time 3-dimensional
TEE were performed prior to the procedure to exclude
intracardiac thrombi and record baseline characteristics,
notably conditions possibly associated with increased risk
for thrombus formation: left ventricular ejection fraction
(EF), LAA ﬂow velocities, left atrial volume, transmitral
gradient, mitral valve area, and spontaneous echocardio-
graphic contrast, which was graded semiquantitatively
in a score between 0 (none) up to 4 (severe) (5). Mitral
regurgitation severity was scored from 4 (mild) to 12
(severe) (6).
Intraprocedural real-time 3-
dimensional TEE documented
the safe placement of the device
and its position. TEE follow-up
was performed before discharge
and after 3, 6, and 12 months to
document device position,
remaining ﬂow within the LAA,
and freedom from pericardial
effusion or thrombus formation.
Hemostaseology. Twenty-four
of the initial 34 patients gave
informed consent and the local
ethics committee approved
a retrospective analysis of coag-
ulation status. Five of the initial
6 patients with thrombus
formation were included in this
analysis. Factor 2 G20210 (7)
and 5 G1691A polymorphisms
(8) were identiﬁed. Methyl-
enetetrahydrofolate reductase
C677T and A1298C poly-
morphisms, which are related to hyperhomocysteinemia,
were examined (9). Genetic mutations in the cytochrome
P450 CYP2C19 locus (10) were checked for the *2, *3, and
*17 variants (11). The PON1 AA variant as 1 determinant
of clopidogrel resistance was examined (12). Antithrombin
3, factor 8, protein C and S activities, and the presence of
lupus anticoagulant were determined.
Statistics. Data were analyzed with SPSS Statistics (version
19, IBM Corp., Somers, New York) and presented as mean
 SD for normally or as medians (interquartile range) for
non-normally distributed items. Univariate analysis of vari-
ance for normally or Mann-Whitney U test for non-
normally distributed items were performed for continuous
variables. Chi-square test was performed for dichotomous
parameters. A p value <0.05 was considered signiﬁcant.
Figure 1. Key Steps of ACP Implantation
(A) Angiography of left atrial appendage (LAA) anatomy and size of landing zone (red bar). (B) Development of lobe by advancing Amplatzer Cardiac Plug (ACP)
out of the sheath. (C) Incompletely unfolded it shows a spherical shape. (D) Complete device development reveals tire shape of the anchored lobe. (E) Release of the
shield covering the LAA entrance. (F) Final position of ACP in relation to mitral valve (MV).
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608Results
Patient characteristics. Twenty patients had paroxysmal AF,
and 14 of those had persisting or permanent AF (Table 1).
CHADS2 score was 3.2  1.2, CHA2DS2-VASc score was
5.5  1.4, and HAS-BLED score was 4.2  1.1. Except
for 2, all patients were on oral anticoagulants prior to the
procedure. Except for 1 patient on permanent AF after
mitral valve reconstruction 10 years before, all patients had
nonvalvular AF.
Procedural data. In all patients, the procedure was per-
formed successfully within 68  38 min, and the occluder
size was 24.1  3.1 mm (range: 18 to 30 mm). In 13
patients, the ACP disk covered the LAA rim, whereas in the
other patients, a deeper implantation of the device into
the LAA was necessary. Two patients experienced post-Figure 2. Placement of ACP
(A) Photo composition of optimal placement of ACP with placement of disk onto th
complete LAA. (B) Optimal placement of ACP (*) covering the rim. (C) Placement of
in Figure 1.interventional pericardial effusion without hemodynamic
relevance; 1 additional patient needed pericardiocentesis. No
periprocedural stroke was detected. Two patients needed
blood transfusions after groin bleeding.
Echocardiography. In 32 patients, a pre-discharge TEE was
performed 3.6  1.7 days after the procedure; 2 patients
refused the examination. In all examined patients, the
ACP occluder was safely anchored in the LAA. In 3 patients,
there was slight residual ﬂow within the LAA. In 3 patients,
a thrombotic mass on the LAA occluder was detected (Fig. 3);
2 patients received intravenous heparin, and complete
thrombus resolution was achieved in the ﬁrst patient. In the
second patient, a thrombus recurred after initial partial reso-
lution followed by an attempt of oral anticoagulation with
dabigatran. Complete resolution was achieved after switching
toVKA(Fig. 4).A third patientwas immediately put onVKA.e lobe anchored in the landing zone behind the entrance with exclusion of
ACP in deeper position within LAA not covering the rim. Abbreviations as
Table 1. Patient Characteristics
Overall
(n ¼ 34)
No Thrombus
(n ¼ 28)
Thrombus
(n ¼ 6) p Value
Age, yrs 74.0  7.8 73.7  8.2 75.3  6.6 0.668
Male 17 (50) 14 (50) 3 (50) d
Paroxysmal AF 20 (59) 16 (57) 4 (67) 0.678
CHADS2 score 3.2  1.2 2.9  1.1 4.3  1.0 0.005*
CHA2DS2-VASc score 5.5  1.4 5.2  1.3 6.8  0.8 0.006*
HAS-BLED score 4.2  1.1 4.1  1.1 4.7  1.2 0.298
Device size, mm 24.1  3.1 24.4  2.9 22.7  3.7 0.475
Device covering rim 13 (38) 11 (39) 2 (33) 0.785
Platelet count/nl 227.7  71.3 215.9  63.9 282.5  84.4 0.036*
Fibrinogen, mg/dl 367.4  101.2 371.9  105.7 347.8  84.5 0.607
Creatinine, mg/dl 1.21 (0.45) 1.24 (0.45) 1.13 (0.43) 0.456
Hemodialysis 1 (3) 1 (4) 0 (0) 0.638
Diabetes 11 (32) 9 (32) 2 (33) 0.995
Ejection fraction, % 48.7  11.9 50.6  11.4 39.7  10.6 0.039*
LA volume indexed, ml/m2 48.6  19.9 46.9  20.8 56.6  14.2 0.285
LAA velocity, cm/s 48.4  24.3 51.3  25.1 36.8  17.7 0.194
Spontaneous echo contrast score 1.4  0.8 1.3  0.9 1.5  0.5 0.632
Mean transmitral gradient, mm Hg 1 (1) 1 (0.98) 1.25 (1) 0.535
Mitral valve area, cm2 3.8  1.0 3.8  1.0 4.2  0.9 0.297
Mitral regurgitation score 6.2  0.5 6.1  1.7 6.7  1.9 0.478
Values are mean  SD or absolute value (%).d ¼ no signiﬁcance test was perfomed. *Statistical signiﬁcance.
AF ¼ atrial ﬁbrillation; CHADS2¼ Congestion, Hypertension, Age, Diabetes, and Stroke; CHA2DS2-VASc¼ CHADS2 Plus Vascular Disease and Sex;
HAS-BLED¼Hypertension, Abnormal Liver or Renal Function, Stroke, Bleeding, Labile International Normalized Ratio, Elderly, Drug or Alcohol Intake;
LA ¼ left atrium; LAA ¼ left atrial appendage.
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609The on-site follow-up rate for the cohort at 3 months
was 88%, whereas the other patients were followed up by
phone call. In all examined patients, the ACP was still
safely anchored in the LAA. Residual ﬂow was still
detectable in the above-mentioned 3 patients. Three addi-
tional patients were found to have a thrombus on the ACP.
In 2 of these patients, careful retrospective review of the
pre-discharge TEE revealed very small structures on the
ACP not originally identiﬁed as thrombi. The third patient
had refused a pre-discharge TEE. In all patients, thrombi
were resolved successfully by intravenous heparin or oral
anticoagulation with VKA. Two of the 3 patients with
a thrombus in the pre-discharge TEE had no recurrence,
so VKA were discontinued, whereas the third patient
still had thrombus remnants on the disk and VKA were
continued.
The on-site follow-up rate of the cohort at 6 months was
82%. The ACP was still in place in all patients. Slight
residual ﬂow within the LAA was found in only 1 patient.
No new or recurrent thrombi were detected. The follow-up
in the patient with thrombus remnants at 3-month follow-
up was delayed until 12 months on patient’s request under
continued VKA without any adverse events.
A 12-month follow-up TEE was performed in 74% of
patients. All devices were found to be in place, but minimal
residual ﬂow was detected in 1 patient. No thrombusoccurrence or recurrence was detected. The patient with
remnants in the 3-month follow-up had no thrombi anymore.
No clinically apparent embolic event occurred during
follow-up.
Echocardiographic characterization of thrombi. Except for
Patient #4 (Fig. 4), in whom a massive thrombus covered
the whole device, all thrombi originated from the central
screw. Whereas in Patients #1 to #3, there were smaller
mobile structures, Patients #5 and #6 had adherent thrombi
spreading toward the rim and covering the disk to a varying
extent (Online Fig. 1).
Comparison of patients without and with thrombi. Parox-
ysmal AF was present in 57% of patients without and in
67% with thrombi (Table 1, Online Table 1). There were no
differences in the prevalence of diabetes and renal insufﬁ-
ciency or procedure-related factors such as occluder size or
placement in relation to the rim between both groups. Apart
from EF, echocardiographic parameters were not different
between groups.
However, patients with thrombus had CHADS2 score
3 and CHA2DS2-VASc score 6, resulting in positive
predictive values of 26% and 40%, respectively, and a nega-
tive predictive value of 100%. Pre-procedural EF was lower
in patients with than without thrombi. Five thrombus
patients had an EF <50%, resulting in a positive predictive
value of 38% and a negative predictive value of 95%.
Figure 3. Echocardiography of Thrombus Formation in 2 Patients
(A) Two-dimensional transesophageal echocardiography (TEE) with mobile thrombus in Patient #3 originating from the screw of the ACP (white arrow) detected at 3-
month follow-up. (B) Three-dimensional TEE with black arrows marking the thrombus. The 22-mm ACP covered the rim of the LAA. (C,D) Patient #5 presented with
a thrombus originating in the pre-discharge TEE from the screw toward the LAA rim covering one-ﬁfth of the disk’s surface on a 22-mm ACP not covering the rim
6 weeks after mitral leaﬂet repair with MitraClip (Abbott Vascular, Abbott Park, Illinois). Ptn ¼ patient.
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610Pre-procedural ﬁbrinogen concentration did not differ
between groups; however, platelet count was higher in those
with thrombi. The activities of antithrombin 3, factor 8, and
proteins C and S were not different between groups, positive
lupus anticoagulant tended to be more frequent in patients
with thrombi (Table 2). Factor 2 and 5 mutations were
found in 1 patient each of the nonthrombus group, both
without any thrombotic events. Methylenetetrahydrofolate
reductase mutations were found frequently, but only in
nonthrombus patients. CYP2C19*2 mutations potentially
leading to clopidogrel resistance occurred frequently, always
in heterozygous form with a trend preferring the thrombus-
group. The CYP2C19*3 variant was not found as expected
in our Caucasian cohort. The CYP2C19*17 variant,
which potentially accelerates clopidogrel metabolism with
a higher risk of bleeding, was found quite often in both
groups. The PON1 AA variant, possibly accounting for
reduced clopidogrel activity, was identiﬁed at an equal rate in
both groups.
Discussion
We demonstrate unexpected thrombus formation on the
ACP and, therefore, raise safety concerns for this noveltreatment option in AF patients. The efﬁcacy of LAA
occlusion in patients with AF has been demonstrated in the
PROTECT-AF (Watchman Left Atrial Appendage
System for Embolic Protection in Patients With Atrial
Fibrillation) trial (13) using the Watchman device (Atritech,
Inc., Plymouth, Minnesota).
A recent device for percutaneous LAA occlusion is the
ACP, which consists of a lobe anchored in the LAA and
a connected disk to cover the LAA oriﬁce, assuming that it
provides better protection against thromboembolism
(“paciﬁer principle”) (14). The disk is intended to cover the
rim of the LAA at the oriﬁce of the upper left pulmonary
vein. It is uncertain whether or not the occluder can always
be positioned in this way and whether or not position is
a risk factor for thrombus formation.
Current registry data conﬁrm the feasibility of ACP
implantation in 137 patients with 7% serious complications
(15), including 3 patients with peri-interventional stroke.
Two cases of post-procedural thrombus formation were re-
ported: 1 detected by TEE after 3 months and the cessation
of clopidogrel after 2 months due to lower gastrointestinal
bleeding (16); the second found by TEE 6 months after
dual antiplatelet therapy for 4 weeks and then continuation
of aspirin alone (17). Recently, López-Miniguez et al. (18)
Figure 4. Massive, Nonmobile Thrombus in Patient #4
Initial pre-discharge TEE and multislice computed tomography scan (* ¼ ACP).
The 18-mm ACP did not cover the LAA rim. The thrombus (white and black
arrows)was resolved by intravenous (i.v.) heparin. After 2 weeks, the thrombus
was mobilized; after an additional week, resolution was successful despite
a slight remnant on the screw. The patient was dismissed under dabigatran.
A TEE was performed 1 month later, showing recurrence of thrombus forma-
tion. The therapeutic regime was switched to vitamin K antagonists. Two
months later, thrombi had resolved. Abbreviations as in Figures 1 and 3.
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611reported the detection of thrombi in 5 of 35 ACP implan-
tations, but without detailed analysis of risk factors.
In the PROTECT-AF trial (13), patients received
warfarin for 45 days after Watchman implantation to bridge
the time until its complete endothelial coverage. The device
was anchored in the LAA but did not cover its entrance;
warfarin was replaced after 45 days by dual antiplatelet
therapy until 6 months after implantation. Device-associated
thrombi were observed in 20 of 478 successful implantations
(4.2%), and thrombus-associated stroke rate was 0.3% per
100 patient-years (19). In preliminary data from the ASAP
(ASA Plavix) registry (20), 4 of 116 patients having high
risk for bleeding and receiving only dual antiplatelet therapy
experienced thrombus formation on the Watchman device.
In a meta-analysis of 54 published cases (5 with AF), thrombi
were seen with all commercially available atrial septal defect/
patent foramen ovale occluder devices, preferentially on their
left side (21). In 20 (2%)d4 of them had AFdof 1,000
patients after atrial septal defect/patent foramen ovale occlu-
sion with different devices, thrombi were found, again pref-
erentially on their left side. No signiﬁcant differences were
found in anticoagulation/antiplatelet regimes between
patients without and with thrombi; thrombus resolution was
achieved with anticoagulation in 17 cases (22).
Thrombosis rate in our cohort (17.6%) exceeds those
previously reported (2% to 4.2%) (19,20,22). Potential
explanations relate to post-interventional anticoagulation/
antiplatelet regime, implantation technique, or the ACP
device itself.
Post-interventional anticoagulation/antiplatelet regime. When
placed optimally, the ACP device excludes the LAA
completely by covering the entrance of the LAA, possibly
justifying not recommending VKA. Dual antiplatelet therapy
for 1 month followed by aspirin monotherapy for 5 more
months was then regarded sufﬁcient, but it was not supported
by data. In 10 dogs, the ACP was implanted with no evidence
for thrombus formation on the occluder during 90 days follow-
up; however, the antithrombotic or antiplatelet regime was not
deﬁned (23). Early successful ACP implantations in 2 patients
with dual antiplatelet therapy had no TEE follow-up so that
potential thrombus formation remained unaddressed (24). In
a series of 20patients, no thrombiwere foundduring 12months
under dual antiplatelet therapy; however, CHADS2 was lower
(2.3 1.3) than in our cohort (3.2 1.2) (25).
With close TEE follow-up, we identiﬁed 6 patients in
whom dual antiplatelet therapy did not prevent thrombus
formation. Echocardiographic parameters reﬂecting reduced
ﬂow velocities in the left atrium did not differ between
patients with or without thrombi. Not unexpectedly, higher
CHADS2 or CHA2DS2-VASc scores, along with reduced
EF, were associated with thrombus formation. Reduced
EF is an established risk factor for thrombus formation in
the native LAA of AF patients (26–28) and was strongly
associated with thrombus formation in our analysis. Also,
Table 2. Coagulation Factor Activity and Mutations Related to Coagulopathy
Overall
(n ¼ 24)
No Thrombus
(n ¼ 19)
Thrombus
(n ¼ 5) p Value
AT3 activity, % 100.1  12.7 101.4  13.7 95.0  6.9 0.325
Factor 8 activity, % 183.5  60.1 185.7  61.2 175.1  62.0 0.733
Protein C activity, % 100.1  32.3 104.1  32.2 85.2  31.3 0.254
Protein S activity, % 86.8  27.8 89.1  27.7 79.0  30.1 0.491
Lupus anticoagulant positive 5 (21) 3 (16) 2 (40) 0.236
Factor 2 mutation 1 (4) 1 (5) 0 (0) 0.600
Factor 5 mutation 1 (4) 1 (5) 0 (0) 0.600
MTHFR C677T/A1298C mutation 6 (25) 6 (32) 0 (0) 0.147
CYP2C19*2 variant 6 (25) 4 (21) 2 (40) 0.384
CYP2C19*3 variant 0 (0) 0 (0) 0 (0) d
CYP2C19*17 variant 10 (42) 7 (37) 3 (60) 0.350
PON1 AA variant 11 (46) 9 (47) 2 (40) 0.769
Values are mean  SD or absolute value (%). d ¼ no signiﬁcance test was performed.
AT3 ¼ antithrombin 3; CYP ¼ cytochrome P450; MTHFR ¼ methylenetetrahydrofolate reductase; PON ¼ paraoxonase.
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612pre-interventional platelet count was higher in the thrombus
group, yet within the physiologic range. Yuce et al. (28)
reported no association of platelet counts with left atrial
thrombosis risk. In contrast, in acute coronary syndromes,
higher platelet count is associated with worse prognosis
(29,30). Possibly, the platelet responsedhere to implanta-
tion of foreign material into the LAAdis disproportionate
even in highly normal platelet counts, emphasizing the
importance of effective platelet inhibition. Retrospectively,
we found no genetic risk for clopidogrel resistance or
other coagulation disorders in patients with thrombi.
The high rate of post-interventional thrombi on the
occluder indicates that dual antiplatelet inhibition was not
sufﬁciently protective. This emphasizes the need for oral
anticoagulation with VKA, in line with the PROTECT AF
trial (13) in which all patients received oral anticoagulation
for 45 days after implantation followed by dual antiplatelet
therapy for 6 months and had fewer thrombi. A risk-stratiﬁed
anticoagulation/antiplatelet regime appears justiﬁed according
to our results, given that patients with low risk scores and
good EF developed no thrombi on dual antiplatelet therapy,
with negative predicted value for EF >50%, CHADS2
score <3, and CHA2DS2-VASc score <6 between 95% and
100%. This notion is supported by Lam et al. (25), who
reported 20 patients with CHADS2 of 2.3  1.3 and no
device thrombosis, similar to our 28 nonthrombus patients
with CHADS2 of 2.0  1.1. Data from a larger prospective
trial are needed to conﬁrm this concept of adjusting the post-
implantation antiplatelet/anticoagulation regime to the indi-
vidual risk proﬁle. As a consequence, from the current data
of our ﬁrst 34 patients, we now put all patients on VKA post-
interventionally until thenextTEEfollow-up (usually 3months)
for safety reasons until more meaningful data are available.
Potential rebound effects after clopidogrel cessation
are unlikely in our cohort due to reliable compliance toclopidogrel. TEE follow-up after clopidogrel cessation did
not show any thrombi.
Implantation technique. The optimal ACP position ac-
cording to the manufacturer’s recommendation was not
achieved in more than 60% of the cases and is possibly a risk
factor for thrombus formation by forming a region of slow
ﬂow in the LAA. However, the number of implants not
covering the rim of the LAA was equal in patients without
and with thrombi. If lack of coverage of the LAA would
result in higher thrombus risk, a higher incidence would be
expected from the Watchman device (19).
ACP device itself. Most thrombi originated from the central
screw, suggesting it may need to be modiﬁed. The surface of
the ACP is larger than that of the Watchman, possibly
explaining the higher numbers of thrombi (20). Device-
related factors may act in cooperation with individual risk
factors in the initiation of thrombosis on the device.
Finally, our study emphasized the use of close TEE
follow-up as all patients with thrombi were identiﬁed in
the pre-discharge TEE or at 3-month follow-up, enabling
initiation of adequate anticoagulation to avoid thrombus
progression and resolve clots before apparent embolic events.
Study limitations. Our hemostaseological evaluation included
platelet count, but no function test before ACP implantation.
The study cohort is still small. Prospective studies are
necessary to deﬁne the optimal risk-stratiﬁed antiplatelet/
anticoagulation strategy.
Conclusions
Percutaneous LAA occlusion is a novel option for patients
with AF and high bleeding risk under VKA. We identiﬁed
several patients with thrombus formation on the ACP
device and higherCHADS2 andCHA2DS2-VASc scores and
platelet counts and notably reduced EF <50% as risk factors.
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613Our study emphasizes the need for close TEE follow-up.
Post-interventional dual antiplatelet therapy does not
protect from thrombus formation; therefore, VKA must be
considered in the critical post-implantation phase until
prospective studies have demonstrated that dual antiplatelet
therapy is safe in patients with a low risk proﬁle.
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For detailed clinical characteristics of the thrombus patients and compar-
ative overview of the echocardiographic thrombus appearance, please see
the online version of this paper.
